Companion diagnostics refers to diagnostic tests that are used in determining the presence of biomarkers in the patents for efficient decision making on the best treatment to use especially the molecular basis of many diseases today is being established. Companion diagnostics are most commonly used in oncology as they are vital for choosing patients who likely will benefit from some of the targeted treatments due to the genetic profile of the tumor. These tests are gradually becoming incorporated into patient’s management plans to make sure that the therapies that are given to patients are accorded to their specific genetic makeup, making the treatment more effective while reducing the side effects.

Complete Blood Count Device Market Size Was Valued at USD 4.2 Billion in 2023, and is Projected to Reach USD 8.7 Billion by 2032, Growing at a CAGR of 8.3% From 2024-2032. The Complete Blood Count (CBC) Device Market includes the manufacturing and supply chain, as well as the use of instruments in evaluating blood tests. These devices analyse numerous parameters, the red blood cell count, white blood cell count, red blood cell haemoglobin, red blood cell volume percentage and platelets, to help determine the general well-being of a patient. CBC devices play vital role in the diagnosis of infections, anemias, and leukemia and is used in hospitals, diagnostic laboratories, and research institutions